Key result
Cell-derived microparticles, particularly endothelial MPs, show promise as circulating biomarkers for predicting future adverse cardiovascular events in patients with acute coronary syndromes.
Why the study?
Patients with ACS remain at increased risk for adverse cardiovascular events and their prognosis is difficult to determine, prompting an evaluation of the predictive role of cell-derived microparticles.
Do cell-derived microparticles predict future adverse cardiovascular events in patients with acute coronary syndromes?
Population
Patients with ACS
Design
Review
Authors
Loading...
Should not yet alter ACS risk assessment; leaves open endothelial microparticles' utility as biomarkers pending validation.
Do cell-derived microparticles predict future adverse cardiovascular events in patients with acute coronary syndromes?
Cell-derived microparticles, particularly endothelial MPs, hold promise as potential circulating biomarkers for predicting adverse cardiovascular events in patients with acute coronary syndromes, though large-scale studies are needed.
Zacharia et al. (2019) conducted a review in Acute Coronary Syndromes. Cell-derived Microparticles (MPs) was evaluated on Predictive role of MPs for future adverse cardiovascular events. Cell-derived microparticles, particularly endothelial MPs, show promise as circulating biomarkers for predicting future adverse cardiovascular events in patients with acute coronary syndromes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: